本文观察重组人尿激酶原在急性ST段抬高性型心肌梗死中应用的疗效评价。采取符合溶栓标准的急性ST段提高型心肌梗死患者66例，随机、单盲分为试验组（33例）及对照组（33例），观察治疗用药120分钟的临床冠脉开通率及择期（7～10天）冠状动脉造影后所示的冠脉开通率的比较，结果显示：试验组的开通率比对照组高。在对急性ST段抬高型心肌梗死患者的溶栓治疗中，应用重组人尿激酶原较尿激酶的疗效要更佳。%To evaluate the Curative effect evaluation of recombinant human prourokinase in acute ST segment elevation myocardial infarction. 66 patients with acute ST segment elevation myocardial infarction Accord with standard of thrombolysis were selected. Randomized, single-blind divided into experimental group (33 cases) and control group (33 cases),Clinical coronary artery patency of TUE 120 minutes were observed and coronary artery patency Elective (7-10 days) after coronary angiography shown results were compared. the results show: the opening rate of the experimental group was higher than the control group. Conclusion was thrombolytic therapy of acute ST segment elevation myocardial infarction Accord with standard of thrombolysis, the efifcacy of Recombinant human prourokinase is better than the urokinase.
展开▼
